查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1726349

全球下一代組織生物標記市場：市場規模、佔有率、趨勢分析（按產品類型、技術、應用、最終用途和地區）、細分市場預測（2025 年至 2030 年）

Next Generation Tissue Biomarkers Market Size, Share & Trends Analysis Report By Product (Reagents & Assays, Instruments & Platforms), By Type (Genomic, Proteomic), By Technology, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

下一代組織生物標記市場的成長與趨勢：

根據 Grand View Research, Inc. 的最新報告，全球下一代組織生物標記市場規模預計到 2030 年將達到 59.8 億美元，預測期內的複合年成長率為 12.74%。

慢性病盛行率上升、生物標記檢測技術的進步以及個人化醫療需求的不斷成長等關鍵促進因素正在推動市場成長。糖尿病、癌症和其他自體免疫疾病等慢性疾病的發生率在全球範圍內不斷增加。

檢測下一代組織生物標記的技術進步不斷推動市場的成長。次世代定序（NGS）等高通量篩檢技術的發展，大大提升了我們分析癌症組織中基因突變和基因表現的能力。此外，液態切片、高通量篩檢技術、表觀遺傳分析和基於微型RNA的生物感測器正在投入實用化，用於下一代組織生物標記檢測。總的來說，這些技術進步正在改變組織生物標記發現的格局，從而實現更準確的診斷、個人化的治療策略和改善患者的治療效果。人工智慧和機器學習演算法正在被納入數位病理學，以自動分析組織影像。個人化醫療需求的不斷成長也是推動市場成長的一個主要因素。在這種個人化醫療中，下一代組織生物標記擴大被用於為個別患者量身定做治療方案。

在生物標記檢測方面，表觀基因基因體學研究工具公司AlidaBio於2025年2月正式宣布全面商業化其EpiPlex平台。此突破性平台首次透過短讀測序同時檢測和量化多種RNA修飾，同時也提供基因表現數據。

2025 年 2 月，提供基因組解決方案的公司 Biofidelity 宣布了有關推出 Enspyre 的詳細資訊，Enspyre 是一項具有廣泛應用潛力的創新目標富集技術。一項突破性的目標富集技術，透過選擇性去除背景 DNA，顯著提高次世代定序(NGS) 的效率。

2024 年 9 月，RNA 生物標記公司 Genialis 宣布推出 Genialis krasID，這是第一個能夠預測不同組織類型和突變類型的患者對 KRAS 抑制劑 (KRASi) 的反應和臨床效用的生物標記演算法。 Genialis krasID 可以幫助指南藥物開發，從早期臨床前階段（例如化合物/MOA 區分和選擇）到臨床試驗。

2024年10月，另一種新型老化細胞標靶分子被開發出來。 Illumina 公司是一家 DNA定序和基於陣列的技術公司，今天推出了 MiSeq i100 系列定序系統，該系統具有無與倫比的台式速度和易用性，可為實驗室中的次世代定序(NGS) 提供支援。

2021年9月，羅氏宣布推出AVENIO腫瘤組織CGP試劑盒。新套件增強了羅氏和 Foundation Medicine 現有的 CGP 產品組合，使實驗室能夠在內部進行更廣泛的腫瘤學研究。該公司表示，該套件的推出將為無法透過集中實驗室進行公司測試的實驗室提供內部解決方案，從而顯著增加全球對基因組分析的訪問。

下一代組織生物標記市場：分析概述

  • 按產品分類，試劑和測定法在 2024 年佔據了最大的收入佔有率，為 55.97%。由於該領域廣泛適用於生物製藥研究，預計將迅速擴張。主要促進因素是對疾病早期檢測和診斷的需求不斷增加，這反過來又增加了對準確、可靠和快速診斷的需求，從而促進了市場成長。
  • 根據類型，基因生物標記部分在 2024 年佔據了市場主導地位。這是由於對創新治療方法的需求不斷成長、對早期疾病檢測的競爭加劇以及大量的研發投資。預計代謝組生物標記在預測期內成長最快。代謝組學生物標記是對體內特定代謝變化或物質的測量，可用於識別疾病狀態、預測疾病風險和監測治療反應。
  • 從技術角度來看，次世代定序領域在 2024 年佔據了市場主導地位，收益佔有率最大。次世代定序(NGS) 是指有助於基因組發現的大規模 DNA定序方法。預計 2024 年至 2030 年間，空間基因組生物學領域將以最快的複合年成長率成長。 CRISPR/Cas9 系統等基因組編輯工具的進步正在促進空間基因組生物學的應用，從而推動市場成長。
  • 根據應用，腫瘤學領域在 2024 年佔據市場主導地位，收益佔有率最大。精準醫療日益成長的需求正在推動該領域和針對性癌症治療的發展。預計伴隨診斷在預測期內成長最快。伴隨診斷市場正在經歷快速的產品擴張，針對各種癌症類型、自體免疫疾病和神經系統疾病的新檢測方法正在開發中。
  • 根據最終用途，醫院和參考實驗室部門將主導市場，並在 2024 年佔據最大的收益佔有率。醫院和參考實驗室正在迅速採用下一代組織生物標記來提高效率、準確性和可近性。預計預測期內 CRO 將大幅成長。

目錄

第1章 分析方法與範圍

第2章執行摘要

3. 下一代組織生物標記市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 下一代組織生物標記市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL分析

第4章 下一代組織生物標記市場：按產品分類的預測和趨勢

  • 細分儀表板
  • 下一代組織生物標記市場：依產品變異分析
  • 下一代組織生物標記市場規模及產品趨勢分析（2018-2030）
  • 試劑和測定法
  • 設備和平台
  • 軟體和人工智慧

第5章：下一代組織生物標記市場：按類型進行估計和趨勢分析

  • 按類型分類的市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 下一代組織生物標記市場：按類型分類的展望
  • 按類型分類的市場規模預測和趨勢分析（2018-2030）
  • 基因生物標記
  • 蛋白質體生物標記
  • 蛋白質體生物標記
  • 表觀遺傳生物標記
  • 轉錄組生物標記
  • 代謝體學學生物標記

第6章：下一代組織生物標記市場：按技術分類的估值和趨勢

  • 按技術分類的市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 下一代組織生物標記市場：依產品變異分析
  • 下一代組織生物標記市場規模與產品趨勢分析（2018-2030）
  • 免疫組織化學
  • 次世代定序（NGS）
  • 基於質譜（MS）的蛋白質體學
  • 太空生物學平台
  • 數位病理學和人工智慧分析
  • 其他

第7章 下一代組織生物標記市場：按應用的估算和趨勢分析

  • 按應用分類的市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 下一代組織生物標記市場：按應用進行差異分析
  • 下一代組織生物標記市場規模與應用趨勢分析（2018-2030）
  • 瘤
  • 伴隨診斷
  • 藥物研發
  • 神經病學
  • 其他

第8章 下一代組織生物標記市場：最終用途估計與趨勢分析

  • 按最終用途分類的市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 下一代組織生物標記市場：按最終用途的變化分析
  • 下一代組織生物標記市場規模和趨勢分析（按最終用途） (2018-2030)
  • 醫院/參考實驗室
  • 製藥和生物技術公司
  • 學術研究所
  • CRO（合約業務組織）

第9章：下一代組織生物標記市場：區域估計和趨勢分析

  • 各地區市場佔有率分析（2024 年及 2030 年）
  • 市場儀表板：按地區
  • 全球市場概況：按地區
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第10章 競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • 主要客戶
    • 主要企業市場佔有率分析（2024年）
    • Roche Diagnostics/Ventana Medical Systems
    • Agilent Technologies/Dako
    • Thermo Fisher Scientific
    • Leica Biosystems（Danaher Corporation）
    • Illumina
    • Qiagen
    • NeoGenomics
    • NanoString Technologies
    • Akoya Biosciences
    • Bio-Techne/ACD
    • Guardant Health
Product Code: GVR-4-68040-555-5

Next Generation Tissue Biomarkers Market Growth & Trends:

The global next generation tissue biomarkers market size is anticipated to reach USD 5.98 billion by 2030 and is projected to grow at a CAGR of 12.74% during the forecast period, according to a new report by Grand View Research, Inc. Key driving factors such as increasing prevalence of chronic diseases, technological advancements in biomarker detection techniques, and rising demand for personalized medicines are responsible for market growth. There is a global increase in the incidence of chronic diseases such as diabetes, cancer, and other autoimmune diseases.

Increasing technological advancements for detecting next generation tissue biomarkers boost the growth of the market. The development of high throughput screening technologies such as next-generation sequencing (NGS) has significantly enhanced the ability to analyze genetic mutations and gene expression profiles in cancer tissues. Furthermore, liquid biopsies, high throughput screening technologies, epigenetic profiling, and microRNA-based biosensors are in practice for next generation tissue biomarker detection. Collectively, these technological advancements are transforming the landscape of tissue biomarker discovery, leading to more accurate diagnostics, personalized treatment strategies, and improved patient outcomes. AI and machine learning algorithms are being incorporated into digital pathology, automating the analysis of tissue images. The growing demand for personalized medicines is another key factor responsible for market growth. These personalized medicines are increasingly leveraging next-generation tissue biomarkers to tailor treatments to individual patients.

For the detection of biomarkers, in February 2025, Alida Biosciences (AlidaBio), a company in epigenomic research tools, officially announced the full commercial launch of its EpiPlex platform. This groundbreaking platform is the first to simultaneously detect and quantify multiple RNA modifications through short-read sequencing while also providing gene expression data.

In February 2025, Biofidelity, a provider of genomic solutions, unveiled details about the launch of Enspyre, an innovative target enrichment technology with a wide range of potential applications. A groundbreaking target enrichment technology that greatly improves next-generation sequencing (NGS) efficiency by selectively eliminating background DNA.

In September 2024, Genialis, an RNA biomarker company, announced the launch of Genialis krasID, the first biomarker algorithm capable of predicting patient response and clinical benefit to KRAS inhibitors (KRASi) across different tissue histologies and mutation types. Genialis krasID can assist in guiding drug development from early preclinical stages, such as compound/MOA differentiation and selection, to clinical trials.

Another novel senescent cell targeting molecules was developed in October 2024. Illumina, Inc., a company in DNA sequencing and array-based technologies, introduced its MiSeq i100 Series of sequencing systems today, offering unmatched benchtop speed and ease of use to enhance next-generation sequencing (NGS) in laboratories.

In September 2021, Roche announced the release of the AVENIO Tumor Tissue CGP Kit. This new kit enhances the existing CGP portfolio from Roche and Foundation Medicine, enabling laboratories to conduct more extensive oncology research in-house. The introduction of this kit will greatly increase global access to genomic profiling by offering an in-house solution for those unable to access our tests through centralized laboratories, the company stated.

Next Generation Tissue Biomarkers Market Report Highlights:

  • Based on product, reagents and assays accounted for the largest revenue share of 55.97% in 2024. This segment is expected to see rapid expansion due to its broad applicability in biopharmaceutical research. A key driving factor is the growing need for early disease detection and diagnostics, which has resulted in high demand for accurate, reliable, and rapid diagnostics, contributing to market growth.
  • Based on type, the genomic biomarker segment dominated the market in 2024 owing to the rising demand for innovative therapies, growing competition for early disease detection, and significant R&D investments. Metabolomic biomarkers are expected to grow fastest over the forecast period. Metabolomic biomarkers refer to specific metabolic changes or substances in the body that can be measured and used to identify disease states, predict disease risk, and monitor responses to treatments.
  • Based on technology, the next generation sequencing segment dominated the market with the largest revenue share in 2024. Next Generation Sequencing (NGS) refers to the huge DNA sequencing methods that aid in genomic discovery. The spatial genomics biology segment is anticipated to witness growth at the fastest CAGR from 2024 to 2030. The advancements in genome editing tools, such as the CRISPR/Cas9 system, have facilitated spatial genomics biology adoption, driving market growth.
  • Based on application, the oncology segment dominated the market with the largest revenue share in 2024. The growing demand for precision medicine drives the segment growth and targeted cancer therapies. Companion diagnostics are expected to grow fastest over the forecast period. The companion diagnostics market is experiencing significant product expansion, with new assays being developed for various cancer types, autoimmune diseases, and neurological disorders.
  • Based on end use, the hospitals & reference labs segment dominated the market with the largest revenue share in 2024. Hospitals and reference labs are rapidly adopting next generation tissue biomarkers to enhance efficiency, accuracy, and accessibility. Contract research organizations are projected to grow significantly during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Technology
    • 1.2.3. Application
    • 1.2.4. Type
    • 1.2.5. End Use
    • 1.2.6. Regional scope
    • 1.2.7. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Technology outlook
    • 2.2.3. Application outlook
    • 2.2.4. Type outlook
    • 2.2.5. End Use outlook
    • 2.2.6. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Next Generation Tissue Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rise of Precision Medicine and Companion Diagnostics
      • 3.2.1.2. Technological Advancements in Spatial Biology and NGS
      • 3.2.1.3. Expansion of Clinical Utility Across Disease Areas
      • 3.2.1.4. Growth in Digital Pathology and AI-Driven Analysis
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Multi-Omic Platforms and Reagents
      • 3.2.2.2. Data Privacy and Infrastructure Barriers in AI Adoption
  • 3.3. Next Generation Tissue Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Next Generation Tissue Biomarkers Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Next Generation Tissue Biomarkers Market: Product Movement Analysis
  • 4.3. Next Generation Tissue Biomarkers Market Size & Trend Analysis, by product, 2018 to 2030 (USD Million)
  • 4.4. Reagents & Assays
    • 4.4.1. Reagents & Assays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Instruments & Platforms
    • 4.5.1. Instruments & Platforms Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Software & AI
    • 4.6.1. Software & AI Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Next Generation Tissue Biomarkers Market: Type Estimates & Trend Analysis

  • 5.1. Type Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Next Generation Tissue Biomarkers Market by Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Genomic Biomarkers
    • 5.5.1. Genomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Proteomic Biomarkers
    • 5.6.1. Proteomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Proteomic Biomarkers
    • 5.7.1. Proteomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Epigenetic Biomarkers
    • 5.8.1. Epigenetic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. Transcriptomic Biomarkers
    • 5.9.1. Transcriptomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.10. Metabolomic Biomarkers
    • 5.10.1. Metabolomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Next Generation Tissue Biomarkers Market: Technology Estimates & Trend Analysis

  • 6.1. Technology Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Next Generation Tissue Biomarkers Market by Technology Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Immunohistochemistry
    • 6.5.1. Immunohistochemistry Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Next-Generation Sequencing (NGS)
    • 6.6.1. Next-Generation Sequencing (NGS) Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Mass Spectrometry (MS)-based Proteomics
    • 6.7.1. Mass Spectrometry (MS)-based Proteomics Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Spatial Biology Platforms
    • 6.8.1. Spatial Biology Platforms Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. Digital Pathology & AI Analysis
    • 6.9.1. Digital Pathology & AI Analysis Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.10. Others
    • 6.10.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Next Generation Tissue Biomarkers Market: Application Estimates & Trend Analysis

  • 7.1. Application Market Share, 2024 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Next Generation Tissue Biomarkers Market by Application Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.5. Oncology
    • 7.5.1. Oncology Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Companion Diagnostics
    • 7.6.1. Companion Diagnostics Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Drug Discovery & Development
    • 7.7.1. Drug Discovery & Development Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Neurology
    • 7.8.1. Neurology Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. Others
    • 7.9.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Next Generation Tissue Biomarkers Market: End Use Estimates & Trend Analysis

  • 8.1. End Use Market Share, 2024 & 2030
  • 8.2. Segment Dashboard
  • 8.3. Next Generation Tissue Biomarkers Market by End Use Outlook
  • 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.5. Hospitals & Reference Labs
    • 8.5.1. Hospitals & Reference Labs Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Pharma & Biotech Companies
    • 8.6.1. Pharma & Biotech Companies Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Academic and Research Institutes
    • 8.7.1. Academic and Research Institutes Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Contract Research Organizations (CROs)
    • 8.8.1. Contract Research Organizations (CROs) Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Next Generation Tissue Biomarkers Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Share Analysis, 2024 & 2030
  • 9.2. Regional Market Dashboard
  • 9.3. Global Regional Market Snapshot
  • 9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 9.5. North America
    • 9.5.1. North America
    • 9.5.2. U.S.
      • 9.5.2.1. Key country dynamics
      • 9.5.2.2. Regulatory framework/Reimbursement
      • 9.5.2.3. Competitive scenario
      • 9.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.3. Canada
      • 9.5.3.1. Key country dynamics
      • 9.5.3.2. Regulatory framework/Reimbursement
      • 9.5.3.3. Competitive scenario
      • 9.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.4. Mexico
      • 9.5.4.1. Key country dynamics
      • 9.5.4.2. Regulatory framework/Reimbursement
      • 9.5.4.3. Competitive scenario
      • 9.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6. Europe
    • 9.6.1. Europe
    • 9.6.2. UK
      • 9.6.2.1. Key country dynamics
      • 9.6.2.2. Regulatory framework/Reimbursement
      • 9.6.2.3. Competitive scenario
      • 9.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.3. Germany
      • 9.6.3.1. Key country dynamics
      • 9.6.3.2. Regulatory framework/Reimbursement
      • 9.6.3.3. Competitive scenario
      • 9.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.4. France
      • 9.6.4.1. Key country dynamics
      • 9.6.4.2. Regulatory framework/Reimbursement
      • 9.6.4.3. Competitive scenario
      • 9.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.5. Italy
      • 9.6.5.1. Key country dynamics
      • 9.6.5.2. Regulatory framework/Reimbursement
      • 9.6.5.3. Competitive scenario
      • 9.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.6. Spain
      • 9.6.6.1. Key country dynamics
      • 9.6.6.2. Regulatory framework/Reimbursement
      • 9.6.6.3. Competitive scenario
      • 9.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.7. Norway
      • 9.6.7.1. Key country dynamics
      • 9.6.7.2. Regulatory framework/Reimbursement
      • 9.6.7.3. Competitive scenario
      • 9.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.8. Sweden
      • 9.6.8.1. Key country dynamics
      • 9.6.8.2. Regulatory framework/Reimbursement
      • 9.6.8.3. Competitive scenario
      • 9.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.9. Denmark
      • 9.6.9.1. Key country dynamics
      • 9.6.9.2. Regulatory framework/Reimbursement
      • 9.6.9.3. Competitive scenario
      • 9.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7. Asia Pacific
    • 9.7.1. Asia Pacific
    • 9.7.2. Japan
      • 9.7.2.1. Key country dynamics
      • 9.7.2.2. Regulatory framework/Reimbursement
      • 9.7.2.3. Competitive scenario
      • 9.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.3. China
      • 9.7.3.1. Key country dynamics
      • 9.7.3.2. Regulatory framework/Reimbursement
      • 9.7.3.3. Competitive scenario
      • 9.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.4. India
      • 9.7.4.1. Key country dynamics
      • 9.7.4.2. Regulatory framework/Reimbursement
      • 9.7.4.3. Competitive scenario
      • 9.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.5. Australia
      • 9.7.5.1. Key country dynamics
      • 9.7.5.2. Regulatory framework/Reimbursement
      • 9.7.5.3. Competitive scenario
      • 9.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.6. South Korea
      • 9.7.6.1. Key country dynamics
      • 9.7.6.2. Regulatory framework/Reimbursement
      • 9.7.6.3. Competitive scenario
      • 9.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.7. Thailand
      • 9.7.7.1. Key country dynamics
      • 9.7.7.2. Regulatory framework/Reimbursement
      • 9.7.7.3. Competitive scenario
      • 9.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8. Latin America
    • 9.8.1. Latin America
    • 9.8.2. Brazil
      • 9.8.2.1. Key country dynamics
      • 9.8.2.2. Regulatory framework/Reimbursement
      • 9.8.2.3. Competitive scenario
      • 9.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.8.3. Argentina
      • 9.8.3.1. Key country dynamics
      • 9.8.3.2. Regulatory framework/Reimbursement
      • 9.8.3.3. Competitive scenario
      • 9.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9. MEA
    • 9.9.1. MEA
    • 9.9.2. South Africa
      • 9.9.2.1. Key country dynamics
      • 9.9.2.2. Regulatory framework/Reimbursement
      • 9.9.2.3. Competitive scenario
      • 9.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.9.3. Saudi Arabia
      • 9.9.3.1. Key country dynamics
      • 9.9.3.2. Regulatory framework/Reimbursement
      • 9.9.3.3. Competitive scenario
      • 9.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.9.4. UAE
      • 9.9.4.1. Key country dynamics
      • 9.9.4.2. Regulatory framework/Reimbursement
      • 9.9.4.3. Competitive scenario
      • 9.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.9.5. Kuwait
      • 9.9.5.1. Key country dynamics
      • 9.9.5.2. Regulatory framework
      • 9.9.5.3. Competitive scenario
      • 9.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 10.2. Company/Competition Categorization
  • 10.3. Vendor Landscape
    • 10.3.1. List of key distributors and channel partners
    • 10.3.2. Key customers
    • 10.3.3. Key company market share analysis, 2024
    • 10.3.4. Roche Diagnostics / Ventana Medical Systems
      • 10.3.4.1. Company overview
      • 10.3.4.2. Financial performance
      • 10.3.4.3. Services benchmarking
      • 10.3.4.4. Strategic initiatives
    • 10.3.5. Agilent Technologies / Dako
      • 10.3.5.1. Company overview
      • 10.3.5.2. Financial performance
      • 10.3.5.3. Services benchmarking
      • 10.3.5.4. Strategic initiatives
    • 10.3.6. Thermo Fisher Scientific
      • 10.3.6.1. Company overview
      • 10.3.6.2. Financial performance
      • 10.3.6.3. Services benchmarking
      • 10.3.6.4. Strategic initiatives
    • 10.3.7. Leica Biosystems (Danaher Corporation)
      • 10.3.7.1. Company overview
      • 10.3.7.2. Financial performance
      • 10.3.7.3. Services benchmarking
      • 10.3.7.4. Strategic initiatives
    • 10.3.8. Illumina
      • 10.3.8.1. Company overview
      • 10.3.8.2. Financial performance
      • 10.3.8.3. Services benchmarking
      • 10.3.8.4. Strategic initiatives
    • 10.3.9. Qiagen
      • 10.3.9.1. Company overview
      • 10.3.9.2. Financial performance
      • 10.3.9.3. Services benchmarking
      • 10.3.9.4. Strategic initiatives
    • 10.3.10. NeoGenomics
      • 10.3.10.1. Company overview
      • 10.3.10.2. Financial performance
      • 10.3.10.3. Services benchmarking
      • 10.3.10.4. Strategic initiatives
    • 10.3.11. NanoString Technologies
      • 10.3.11.1. Company overview
      • 10.3.11.2. Financial performance
      • 10.3.11.3. Services benchmarking
      • 10.3.11.4. Strategic initiatives
    • 10.3.12. Akoya Biosciences
      • 10.3.12.1. Company overview
      • 10.3.12.2. Financial performance
      • 10.3.12.3. Services benchmarking
      • 10.3.12.4. Strategic initiatives
    • 10.3.13. Bio-Techne / ACD
      • 10.3.13.1. Company overview
      • 10.3.13.2. Financial performance
      • 10.3.13.3. Services benchmarking
      • 10.3.13.4. Strategic initiatives
    • 10.3.14. Guardant Health
      • 10.3.14.1. Company overview
      • 10.3.14.2. Financial performance
      • 10.3.14.3. Services benchmarking
      • 10.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Next Generation Tissue Biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 5 North America Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 6 North America Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 7 North America Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 8 U.S Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 9 U.S Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 10 U.S Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 11 U.S Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 12 U.S Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 13 Canada Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 14 Canada Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 15 Canada Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 16 Canada Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 17 Canada Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 18 Mexico Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 19 Mexico Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 20 Mexico Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 21 Mexico Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 22 Mexico Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 23 Europe Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 24 Europe Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 25 Europe Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 26 Europe Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 27 Europe Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 28 UK Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 29 UK Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 30 UK Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 31 UK Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 32 UK Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 33 Germany Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 34 Germany Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 35 Germany Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 36 Germany Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 37 Germany Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 38 France Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 39 France Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 40 France Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 41 France Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 42 France Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 43 Italy Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 44 Italy Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 45 Italy Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 46 Italy Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 47 Italy Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 48 Spain Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 49 Spain Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 50 Spain Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 51 Spain Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 52 Spain Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 53 Denmark Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 54 Denmark Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 55 Denmark Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 56 Denmark Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 57 Denmark Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 58 Sweden Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 59 Sweden Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 60 Sweden Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 61 Sweden Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 62 Sweden Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 63 Norway Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 64 Norway Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 65 Norway Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 66 Norway Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 67 Norway Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 68 Asia Pacific Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 69 Asia Pacific Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 70 Asia Pacific Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 71 Asia Pacific Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 72 Asia Pacific Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 73 Japan Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 74 Japan Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 75 Japan Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 76 Japan Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 77 Japan Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 78 China Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 79 China Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 80 China Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 81 China Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 82 China Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 83 India Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 84 India Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 85 India Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 86 India Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 87 India Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 88 Australia Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 89 Australia Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 90 Australia Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 91 Australia Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 92 Australia Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 93 South Korea Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 94 South Korea Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 95 South Korea Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 96 South Korea Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 97 South Korea Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 98 Thailand Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 99 Thailand Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 100 Thailand Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 101 Thailand Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 102 Thailand Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 103 Latin America Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 104 Latin America Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 105 Latin America Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 106 Latin America Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 107 Latin America Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 108 Brazil Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 109 Brazil Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 110 Brazil Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 111 Brazil Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 112 Brazil Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 113 Argentina Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 114 Argentina Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 115 Argentina Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 116 Argentina Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 117 Argentina Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 118 MEA Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 119 MEA Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 120 MEA Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 121 MEA Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 122 MEA Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 123 South Africa Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 124 South Africa Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 125 South Africa Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 126 South Africa Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 127 South Africa Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 128 Saudi Arabia Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 129 Saudi Arabia Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 130 Saudi Arabia Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 131 Saudi Arabia Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 132 Saudi Arabia Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 133 UAE Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 134 UAE Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 135 UAE Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 136 UAE Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 137 UAE Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)
  • Table 138 Kuwait Next Generation Tissue Biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 139 Kuwait Next Generation Tissue Biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 140 Kuwait Next Generation Tissue Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 141 Kuwait Next Generation Tissue Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 142 Kuwait Next Generation Tissue Biomarkers market, by end user, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Next Generation Tissue Biomarkers market: market outlook
  • Fig. 14 Next Generation Tissue Biomarker competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Next Generation Tissue Biomarkers market driver impact
  • Fig. 20 Next Generation Tissue Biomarkers market restraint impact
  • Fig. 21 Next Generation Tissue Biomarkers market strategic initiatives analysis
  • Fig. 22 Next Generation Tissue Biomarkers market: Product movement analysis
  • Fig. 23 Next Generation Tissue Biomarkers market: Product outlook and key takeaways
  • Fig. 24 Reagents & Assays market estimates and forecast, 2018 - 2030
  • Fig. 25 Instruments & Platforms market estimates and forecast, 2018 - 2030
  • Fig. 26 Software & AI market estimates and forecast, 2018 - 2030
  • Fig. 27 Next Generation Tissue Biomarkers Market: Type movement analysis
  • Fig. 28 Next Generation Tissue Biomarkers market: Type outlook and key takeaways
  • Fig. 29 Genomic Biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 30 Proteomic Biomarkers market estimates and forecasts,2018 - 2030
  • Fig. 31 Epigenetic Biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 32 Transcriptomic Biomarkers market estimates and forecasts,2018 - 2030
  • Fig. 33 Metabolomic Biomarkers market estimates and forecasts, 2018 - 2030
  • Fig. 34 Next Generation Tissue Biomarkers Market: Technology movement analysis
  • Fig. 35 Next Generation Tissue Biomarkers market: Technology outlook and key takeaways
  • Fig. 36 Immunohistochemistry market estimates and forecasts, 2018 - 2030
  • Fig. 37 Next-Generation Sequencing (NGS) market estimates and forecasts,2018 - 2030
  • Fig. 38 Mass Spectrometry (MS)-based Proteomics market estimates and forecasts,2018 - 2030
  • Fig. 39 Spatial Biology Platforms market estimates and forecasts,2018 - 2030
  • Fig. 40 Digital Pathology & AI Analysis market estimates and forecasts,2018 - 2030
  • Fig. 41 Others market estimates and forecasts,2018 - 2030
  • Fig. 42 Next Generation Tissue Biomarkers Market: Application movement analysis
  • Fig. 43 Next Generation Tissue Biomarkers market: Application outlook and key takeaways
  • Fig. 44 Oncology market estimates and forecasts, 2018 - 2030
  • Fig. 45 Companion Diagnostics market estimates and forecasts,2018 - 2030
  • Fig. 46 Drug Discovery & Development market estimates and forecasts,2018 - 2030
  • Fig. 47 Neurology market estimates and forecasts,2018 - 2030
  • Fig. 48 Others market estimates and forecasts,2018 - 2030
  • Fig. 49 Next Generation Tissue Biomarkers market: End Use movement analysis
  • Fig. 50 Next Generation Tissue Biomarkers market: End Use outlook and key takeaways
  • Fig. 51 Hospitals & Reference Labs market estimates and forecasts, 2018 - 2030
  • Fig. 52 Pharma & Biotech Companies market estimates and forecasts,2018 - 2030
  • Fig. 53 Academic and Research Institutes market estimates and forecasts, 2018 - 2030
  • Fig. 54 Contract Research Organizations (CROs) market estimates and forecasts, 2018 - 2030
  • Fig. 55 Global Next Generation Tissue Biomarkers market: Regional movement analysis
  • Fig. 56 Global Next Generation Tissue Biomarkers market: Regional outlook and key takeaways
  • Fig. 57 Global Next Generation Tissue Biomarkers market share and leading players
  • Fig. 58 North America market share and leading players
  • Fig. 59 Europe market share and leading players
  • Fig. 60 Asia Pacific market share and leading players
  • Fig. 61 Latin America market share and leading players
  • Fig. 62 Middle East & Africa market share and leading players
  • Fig. 63 North America
  • Fig. 64 Europe
  • Fig. 65 Asia Pacific
  • Fig. 66 Latin America
  • Fig. 67 MEA
  • Fig. 68 North America, by country
  • Fig. 69 North America
  • Fig. 70 North America market estimates and forecasts, 2018 - 2030
  • Fig. 71 U.S.
  • Fig. 72 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 73 Canada
  • Fig. 74 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 75 Mexico
  • Fig. 76 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 77 Europe
  • Fig. 78 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 79 UK
  • Fig. 80 UK market estimates and forecasts, 2018 - 2030
  • Fig. 81 Germany
  • Fig. 82 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 83 France
  • Fig. 84 France market estimates and forecasts, 2018 - 2030
  • Fig. 85 Italy
  • Fig. 86 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 87 Spain
  • Fig. 88 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 89 Denmark
  • Fig. 90 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 91 Sweden
  • Fig. 92 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 93 Norway
  • Fig. 94 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 95 Asia Pacific
  • Fig. 96 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 97 China
  • Fig. 98 China market estimates and forecasts, 2018 - 2030
  • Fig. 99 Japan
  • Fig. 100 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 101 India
  • Fig. 102 India market estimates and forecasts, 2018 - 2030
  • Fig. 103 Thailand
  • Fig. 104 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 105 South Korea
  • Fig. 106 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 107 Australia
  • Fig. 108 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 109 Latin America
  • Fig. 110 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 111 Brazil
  • Fig. 112 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 113 Argentina
  • Fig. 114 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 115 Middle East and Africa
  • Fig. 116 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 117 South Africa
  • Fig. 118 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 119 Saudi Arabia
  • Fig. 120 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 121 UAE
  • Fig. 122 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 123 Kuwait
  • Fig. 124 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 125 Market share of key market players - Next Generation Tissue Biomarkers market